Remote Digital Physiologic Data Collection in Cancer
This study aims to create a secure way to collect health information from cancer patients using digital tools. Researchers want to understand how this information relates to cancer diagnosis, how well treatments work, and what factors might increase or decrease cancer risk. You might be able to join if you are 18 or older and have a solid tumor, whether it's newly diagnosed, treated in the past, or advanced. The study will also include people without a history of cancer for comparison. The main goal is to set up this data collection system within one year.
- Study design
- This is an observational study that plans to enroll 3692 participants, including people with various types of solid tumors and adults without a history of cancer.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal of establishing the data collection mechanism will be measured at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05390827
Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
Recruiting
Not specifiedAges 18+ObservationalMemorial Sloan Kettering Cancer CenterInvestigator-initiated
~3,692 participants
Updated 2026-07-21 on ClinicalTrials.gov
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
establish a mechanism within the institution to prospectively collect / extract digital remote physiological data among patients with cancer
Measured over 1 year
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Luke Pike, MD, DPhil · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Individuals who meet at least one of the following criteria:
Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor
Historical diagnosis of primary invasive solid tumor
Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
Enrolled onto an investigational trial in the EDD Service
Seen in the MSK UCC from 2021 and onwards
Completion of Survivorship Patient Self-Assessment
Adult without a history of cancer \<50 years of age
Adult without a history of cancer ≥ 50 years of age
≥18 years old
Own an Apple iPhone or Android with valid operating software
Self-reported "very well" comprehension of written and verbal English language
Willing and able to provide informed consent and HIPAA authorization for the release of personal health information
Patients at MSK who are:
Scheduled to undergo any type of BMT (Cohort 1)
Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)
Scheduled to undergo any surgery for prostate cancer (Cohort 3)
Scheduled to undergo any lung cancer surgery (Cohort 4)
Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)
Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6):
High risk/very high localized, locally advanced,
Biochemically recurrent prostate cancer
Treatment naïve, low-volume metastatic prostate cancer
Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7)
Receiving outpatient care at Memorial Sloan Kettering Cancer Center (MSK)(Cohort 10)
Diagnosed with metastatic cancer to bone (Cohort 10)
Scheduled for non-emergent orthopaedic surgery to stabilize lower-extremity bone metastases (Cohort 10)
Able to undergo at least 5 consecutive days of preoperative monitoring prior to surgery (Cohort 10)
Have had a CT scan including the L3 vertebral level within 3 months before surgery (used to assess skeletal muscle mass and sarcopenia) (Cohort 10)
Have a ≥50% predicted likelihood of 6-month postoperative survival, as estimated by the PATHFx clinical decision-support tool (Cohort 10
Individuals without cancer \<50 years of age (Cohort 8)
Individuals without cancer ≥50 years of age (Cohort 9)
18 to 90 years old at the time of consent
Willing and able to download the Withings Health Mate app onto their personal mobile device
Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent for Cohorts 1-9, and 4 months following consent for Cohort 10.
Willing to provide informed consent
Exclusion
Unable or unwilling to successfully export and /or share physiological data
Unable or unwilling to appropriately use digital platforms or devices
Require a wheelchair for ambulation (Cohort 10)
Are undergoing stabilization surgery for a primary bone tumor (rather than metastatic disease) (Cohort 10)
What this trial measures
- establish a mechanism within the institution to prospectively collect / extract digital remote physiological data among patients with cancer1 year
to create a repository and infrastructure to address novel questions of clinical importance.